Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Cancer Test Predicts Treatment Outcome

October 9, 2015 By The University of Queensland

University of Queensland researchers have announced a new tool in the fight against cancer, with the development of a world-first test that will direct treatment choices for patients with some forms of blood cancer.

The test, developed by the UQ Diamantina Institute’s Professor Maher Gandhi, can predict how patients with a specific form of non-Hodgkin’s lymphoma will respond to standard treatment.

Professor Gandhi said results from a landmark study regarding the tool would help clinicians identify the best course of action for patients with Diffuse Large B-Cell Lymphoma (DLBCL).

Leukaemia Foundation Queensland CEO Bill Petch said the test could help patients access newer drugs in the future.

“This isn’t just another test. It’s a game-changer,” Mr. Petch said.

“Professor Gandhi’s discovery will mean patients get access to the best treatment for them, first time, every time.

“It will significantly reduce relapse rates and have a significant impact on how drugs are funded and delivered into the healthcare system.

“The implications for this country’s health economics are enormous but, most importantly, patients will get access to the best treatments more quickly.

“If this test can then translate to other medicines and blood cancers, it could open the door to new drugs from overseas by shedding more light on their potential here in Australia.”

Professor Gandhi said this type of non-Hodgkin’s lymphoma was the sixth most common form of cancer, with up to 2000 Australians are diagnosed each year.

“It can be fast growing and aggressive, so early diagnosis is vital, as is swift treatment,” he said.

“Fortunately, the majority of cases respond very well to the current first line treatment, which is a combination of chemotherapy and immunotherapy.

“However, some patients do not respond, and for these people the prognosis is poor.”

“The test will allow clinicians like myself to determine which patients are unlikely to respond well to standard treatment, thus avoiding ineffective and unnecessary chemotherapy and prompting consideration of other treatment options.”

The Leukaemia Foundation Queensland partly funded the research, which is published in the prestigious Lancet Haematology journal.

Researchers are seeking a provisional patent for the test and are working with commercial partners to develop the technology further.

“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe